{
  "Symbol": "VRTX",
  "AssetType": "Common Stock",
  "Name": "Vertex Pharmaceuticals Inc",
  "Description": "Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.",
  "CIK": "875320",
  "Exchange": "NASDAQ",
  "Currency": "USD",
  "Country": "USA",
  "Sector": "LIFE SCIENCES",
  "Industry": "PHARMACEUTICAL PREPARATIONS",
  "Address": "50 NORTHERN AVENUE, BOSTON, MA, US",
  "OfficialSite": "https://www.vrtx.com",
  "FiscalYearEnd": "December",
  "LatestQuarter": "2024-12-31",
  "MarketCapitalization": "125738181000",
  "EBITDA": "4774600000",
  "PERatio": "None",
  "PEGRatio": "1.309",
  "BookValue": "63.87",
  "DividendPerShare": "None",
  "DividendYield": "None",
  "EPS": "-2.1",
  "RevenuePerShareTTM": "42.73",
  "ProfitMargin": "-0.0486",
  "OperatingMarginTTM": "0.45",
  "ReturnOnAssetsTTM": "0.127",
  "ReturnOnEquityTTM": "-0.0315",
  "RevenueTTM": "11020100000",
  "GrossProfitTTM": "6024300000",
  "DilutedEPSTTM": "-2.1",
  "QuarterlyEarningsGrowthYOY": "-0.056",
  "QuarterlyRevenueGrowthYOY": "0.157",
  "AnalystTargetPrice": "498.43",
  "AnalystRatingStrongBuy": "4",
  "AnalystRatingBuy": "16",
  "AnalystRatingHold": "12",
  "AnalystRatingSell": "1",
  "AnalystRatingStrongSell": "1",
  "TrailingPE": "-",
  "ForwardPE": "27.1",
  "PriceToSalesRatioTTM": "11.41",
  "PriceToBookRatio": "7.48",
  "EVToRevenue": "10.74",
  "EVToEBITDA": "243.46",
  "Beta": "0.506",
  "52WeekHigh": "519.88",
  "52WeekLow": "377.85",
  "50DayMovingAverage": "486.15",
  "200DayMovingAverage": "470.95",
  "SharesOutstanding": "257081000",
  "DividendDate": "None",
  "ExDividendDate": "None",
  "Last Updated": "2025-04-23 14:46:05",
  "Price_Day_1": 490.47,
  "Price_Day_2": 477.52,
  "Price_Day_3": 489.1,
  "Price_Day_4": 485.89,
  "Price_Day_5": 500.49,
  "Price_Day_6": 495.83,
  "Price_Day_7": 484.22,
  "Income_totalRevenue_Q1": "2912000000",
  "Income_grossProfit_Q1": "2488600000",
  "Income_netIncome_Q1": "913000000",
  "Income_totalRevenue_Q2": "2771900000",
  "Income_grossProfit_Q2": "2379300000",
  "Income_netIncome_Q2": "1045400000",
  "Income_totalRevenue_Q3": "2634700000",
  "Income_grossProfit_Q3": "2262800000",
  "Income_netIncome_Q3": "-3593600000",
  "Income_totalRevenue_Q4": "2687200000",
  "Income_grossProfit_Q4": "2344600000",
  "Income_netIncome_Q4": "1099600000",
  "Balance_totalAssets_Q1": "22533200000",
  "Balance_totalLiabilities_Q1": "6123600000",
  "Balance_totalShareholderEquity_Q1": "16409600000",
  "Balance_cashAndCashEquivalentsAtCarryingValue_Q1": "4569600000",
  "Balance_totalAssets_Q2": "22240200000",
  "Balance_totalLiabilities_Q2": "6609300000",
  "Balance_totalShareholderEquity_Q2": "15630900000",
  "Balance_cashAndCashEquivalentsAtCarryingValue_Q2": "5239200000",
  "Balance_totalAssets_Q3": "20132100000",
  "Balance_totalLiabilities_Q3": "5357400000",
  "Balance_totalShareholderEquity_Q3": "14774700000",
  "Balance_cashAndCashEquivalentsAtCarryingValue_Q3": "4580100000",
  "Balance_totalAssets_Q4": "23917400000",
  "Balance_totalLiabilities_Q4": "5370800000",
  "Balance_totalShareholderEquity_Q4": "18546600000",
  "Balance_cashAndCashEquivalentsAtCarryingValue_Q4": "9158000000",
  "Debt to Equity Ratio": 0.37,
  "Is Complete": true
}